Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Common Equity (2020 - 2025)

IceCure Medical (ICCM) has disclosed Common Equity for 5 consecutive years, with $6.9 million as the latest value for Q4 2024.

  • On a quarterly basis, Common Equity fell 43.26% to $6.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $6.9 million, a 43.26% decrease, with the full-year FY2024 number at $6.9 million, down 43.26% from a year prior.
  • Common Equity was $6.9 million for Q4 2024 at IceCure Medical, down from $12.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $27.0 million in Q4 2021 to a low of $5.6 million in Q4 2020.
  • A 5-year average of $15.4 million and a median of $12.2 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 377.3% in 2021, then tumbled 52.16% in 2023.
  • IceCure Medical's Common Equity stood at $5.6 million in 2020, then skyrocketed by 377.3% to $27.0 million in 2021, then fell by 5.7% to $25.4 million in 2022, then tumbled by 52.16% to $12.2 million in 2023, then tumbled by 43.26% to $6.9 million in 2024.
  • Per Business Quant, the three most recent readings for ICCM's Common Equity are $6.9 million (Q4 2024), $12.2 million (Q4 2023), and $25.4 million (Q4 2022).